Treatment and control of dyslipidaemia is needed to reduce or prevent the risk of cardiovascular (CV) disease. Statins reduce CV risk but type 2 diabetes (T2D) patients with increased triglycerides (TGs) and low HDL-C still have a substantial residual risk. Lipanthyl, a fenofibrate, is used to lower triglycerides and lower CV risk. Research suggests that both a statin and a fenofibrate are necessary for adequate CV protection in these patients.